Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.

ABSTRACT: Understanding leukemia heterogeneity is critical for the development of curative treatments as the failure to eliminate therapy-persistent leukemic stem cells (LSCs) may result in disease relapse. Here we have combined high-throughput immunophenotypic screens with large-scale single-cell gene expression analysis to define the heterogeneity within the LSC population in chronic phase chronic myeloid leukemia (CML) patients at diagnosis and following conventional tyrosine kinase inhibitor (TKI) treatment. Our results reveal substantial heterogeneity within the putative LSC population in CML at diagnosis and demonstrate differences in response to subsequent TKI treatment between distinct subpopulations. Importantly, LSC subpopulations with myeloid and proliferative molecular signatures are pro

SUBMITTER: Warfvinge R 

PROVIDER: S-EPMC5484462 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature